Form 4: Sanara MedTech COO Jacob Waldrop Reports Stock Grant and Disposal

Jacob Waldrop, Chief Operating Officer of Sanara MedTech Inc., reports acquisition of restricted stock and disposal of common stock.

Summary

• On February 25, 2025, Jacob A. Waldrop, the Chief Operating Officer of Sanara MedTech Inc., reported a transaction involving the company's stock.
• Waldrop acquired 8,790 shares of common stock as part of a restricted stock grant.
• These shares were granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan.
• Waldrop also disposed of 8,790 shares of common stock.
• Following these transactions, Waldrop beneficially owns 11,891 shares of Sanara MedTech Inc.
• The restricted stock vests in three equal installments on February 25, 2026, 2027, and 2028.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of restricted stock to the COO aligns his interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the COO.

Future Outlook

The restricted stock grant suggests an expectation of continued service and contribution from the COO over the next three years.

Industry Context

Stock grants are a common practice in the MedTech industry to incentivize and retain key executives.

Stakeholder Impact

• The stock grant aligns the COO's interests with those of the shareholders, potentially leading to better company performance.

Key Dates